<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "topotecan inj VIAL>
<dose><value>1</value>
<value>3</value>
<value>1.25</value>
<value>3.75</value>
<value>0.75</value>
<value>2.4</value>
</dose><route><value>IV</value>
</route><form><value>inj VIAL</value>
</form><drugname><value>topotecan inj VIAL</value>
</drugname><strength><value>4 mg</value>
</strength><frequency><value>DAILY</value>
<value>WEEKLY</value>
</frequency><instruction><value>for 5 days. Dilute dose in 50 mL 0.9% sodium chloride and administer over 30 minutes.</value>
<value>for 3 doses. Dilute dose in 50 mL 0.9% sodium chloride and administer over 30 minutes.</value>
</instruction><volume><value></value>
</volume><units><value>mg/m2</value>
</units><additionalnotes><value>Ovarian Cancer, Primary Peritoneal Carcinoma (for Primary Unknown). Dilute dose in 30 to 60 mL 0.9% sodium chloride.For patients with CrCl 20 to 39 mL/minute, reduce dose 50%. Recommend avoiding topotecan in patients with CrCl less than 20 mL/minute.</value>
<value>Ovarian Carcinoma. Dilute dose in 30 to 60 mL 0.9% sodium chloride.For patients with CrCl 20 to 39 mL/minute, reduce dose 50%. Recommend avoiding topotecan in patients with CrCl less than 20 mL/minute.</value>
<value>Advanced Ovarian Carcinoma. Dilute dose in 30 to 60 mL 0.9% sodium chloride.For patients with CrCl 20 to 39 mL/minute, reduce dose 50%. Recommend avoiding topotecan in patients with CrCl less than 20 mL/minute.</value>
<value>Ewings Sarcoma. Dilute dose in 30 to 60 mL 0.9% sodium chloride.For patients with CrCl 20 to 39 mL/minute, reduce dose 50%. Recommend avoiding topotecan in patients with CrCl less than 20 mL/minute.</value>
<value>Neuroblasoma, combination therapy. Dilute dose in 30 to 60 mL 0.9% sodium chloride.For patients with CrCl 20 to 39 mL/minute, reduce dose 50%. Recommend avoiding topotecan in patients with CrCl less than 20 mL/minute.</value>
<value>Neuroblasoma, single agent. Dilute dose in 30 to 60 mL 0.9% sodium chloride.For patients with CrCl 20 to 39 mL/minute, reduce dose 50%. Recommend avoiding topotecan in patients with CrCl less than 20 mL/minute.</value>
</additionalnotes><population><value>ADULT</value>
<value>PEDIATRIC</value>
</population><indicationprn><value></value>
</indicationprn><backgroundinformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3456</value>
</backgroundinformation><prninformation><value></value>
</prninformation><ahsformularystatus><value>Formulary.</value>
</ahsformularystatus><ahfsname><value>Antineoplastic Agents</value>
</ahfsname><highalert><value>YES</value>
</highalert><maximumprndose><value>YES</value>
</maximumprndose></drug>